 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
35 News |  |
- ||||| MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Trial completion date, Trial termination, Trial primary completion date: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 26, 2024
P2, N=60, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2025 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Aug 2024; Lack of Efficacy
- | Amtagvi (lifileucel) / Iovance Biotherap
Trial primary completion date, Metastases: Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Mar 2, 2024
P2, N=12, Recruiting, Sponsor: University of Kansas Medical Center
Trial completion date: Jan 2025 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Aug 2024; Lack of Efficacy Trial primary completion date: Nov 2024 --> Nov 2025
- ||| MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Enrollment change, Trial primary completion date: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jan 11, 2024
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2024 --> Nov 2025 N=27 --> 60 | Trial primary completion date: Jan 2024 --> Jan 2025
- || Amtagvi (lifileucel) / Iovance Biotherap
Enrollment open, Metastases: Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Dec 7, 2023
P2, N=12, Recruiting, Sponsor: University of Kansas Medical Center
N=27 --> 60 | Trial primary completion date: Jan 2024 --> Jan 2025 Not yet recruiting --> Recruiting
- || Amtagvi (lifileucel) / Iovance Biotherap
New P2 trial, Metastases: Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Nov 30, 2023
P2, N=12, Not yet recruiting, Sponsor: University of Kansas Medical Center
- ||||| CIML NK cells / Washington University School of Medicine in St. Louis
Trial completion date, Trial termination: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 1, 2023
P1/2, N=89, Terminated, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial completion date: Dec 2024 --> Apr 2022 | Active, not recruiting --> Terminated; Insufficient funding/staff
- ||| CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Apr 15, 2022
P1/2, N=91, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Dec 2024 --> Apr 2022 | Active, not recruiting --> Terminated; Insufficient funding/staff Recruiting --> Active, not recruiting | N=140 --> 91 | Trial completion date: Sep 2029 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2021
- || CIML NK cells / Washington University School of Medicine in St. Louis
Trial completion date, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jan 28, 2022
P1/2, N=140, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | N=140 --> 91 | Trial completion date: Sep 2029 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2021 Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Sep 2023 --> Sep 2024
- | MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Nov 10, 2021
P2, N=27, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Sep 2021 --> Jan 2025 | Trial primary completion date: Sep 2021 --> Jan 2024
- ||| MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Enrollment closed, Enrollment change: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jun 2, 2021
P2, N=27, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2021 --> Jan 2025 | Trial primary completion date: Sep 2021 --> Jan 2024 Recruiting --> Active, not recruiting | N=60 --> 27
- || Unituxin (dinutuximab) / United Therapeutics Corp
Clinical, P1/2 data, Journal: A Phase I/IIa Study of Antidisialoganglioside Antibody Dinutuximab in Japanese Patients With Neuroblastoma. (Pubmed Central) - May 20, 2021
At the end of the study, survival was confirmed in 22 patients (9 in the M-CSF group and 13 in the G-CSF group). From these results, we concluded that this combination regimen is a feasible treatment for Japanese patients with neuroblastoma.
- | MB-101 / Fortress
Enrollment open, CAR T-Cell Therapy, Metastases, Immune cell: Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov) - Nov 18, 2020
P1, N=24, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
From these results, we concluded that this combination regimen is a feasible treatment for Japanese patients with neuroblastoma. Suspended --> Recruiting
- | CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change, Trial completion date, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=140, Recruiting, Sponsor: Washington University School of Medicine
Suspended --> Recruiting N=70 --> 140 | Trial completion date: Dec 2020 --> Sep 2028 | Trial primary completion date: Dec 2020 --> Sep 2023
- | MB-101 / Fortress
Trial suspension, CAR T-Cell Therapy, Metastases, Immune cell: Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov) - Apr 24, 2020
P1, N=24, Suspended, Sponsor: Jonsson Comprehensive Cancer Center
N=70 --> 140 | Trial completion date: Dec 2020 --> Sep 2028 | Trial primary completion date: Dec 2020 --> Sep 2023 Recruiting --> Suspended
- | CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Mar 10, 2020
P1/2, N=70, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Suspended N=133 --> 70
- | MB-101 / Fortress
Enrollment open, CAR T-Cell Therapy, Metastases, Immune cell: Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov) - Dec 3, 2019
P1, N=24, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
N=133 --> 70 Not yet recruiting --> Recruiting
- | MB-101 / Fortress
New P1 trial, CAR T-Cell Therapy, Metastases, Immune cell: Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov) - Oct 7, 2019
P1, N=24, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Trial completion date: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Nov 6, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Sep 2022 --> Sep 2021
- | MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 23, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2022 --> Sep 2021 Trial completion date: Dec 2020 --> Sep 2022 | Trial primary completion date: Dec 2020 --> Sep 2021
- | MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
Enrollment open: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 20, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2020 --> Sep 2022 | Trial primary completion date: Dec 2020 --> Sep 2021 Not yet recruiting --> Recruiting
- | MDA-TIL / Iovance Biotherap, UT MD Anderson Cancer Center
New P2 trial: NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 1, 2018
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 3, 2018
P1/2, N=133, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=48 --> 133
- | CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 19, 2017
P1/2, N=48, Recruiting, Sponsor: Washington University School of Medicine
N=48 --> 133 Trial primary completion date: Sep 2017 --> Dec 2020
- | CIML NK cells / Washington University School of Medicine in St. Louis
Phase classification, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 12, 2017
P1/2, N=48, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Sep 2017 --> Dec 2020 Phase classification: P1 --> P1/2 | Trial primary completion date: Mar 2017 --> Sep 2017
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change, Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 12, 2016
P1, N=48, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P1 --> P1/2 | Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Dec 2016 --> Mar 2017 | N=24 --> 48
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Aug 15, 2016
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2016 --> Mar 2017 | N=24 --> 48 Trial primary completion date: Aug 2016 --> Dec 2016
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 1, 2016
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Apr 2016 --> Aug 2016
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jan 17, 2016
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Apr 2016 --> Aug 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment open: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Aug 15, 2014
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 26, 2014
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=24 --> 48
- CIML NK cells / Washington University School of Medicine in St. Louis
New P1 trial: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jul 10, 2013
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
Trial completion, Metastases: Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - Oct 10, 2011
P3, N=185, Completed, Sponsor: National Cancer Institute (NCI)
N=24 --> 48 Active, not recruiting --> Completed